Bradykinesia Subscale Administered Alone Versus Regular Administration: Psychometric Properties
Completed
- Conditions
- Parkinson's Disease
- Registration Number
- NCT00932581
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Brief Summary
The purpose of this study is to examine whether scores on questionnaires that rate how much Parkinson's Disease (PD) has slowed movements of the body differ when the order of the questions are changed. The consistency and accuracy of the questionnaires will also be examined. It is hypothesized that there will not be a difference.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 110
Inclusion Criteria
- Male or Female at least 30 years of age
- Willing to be assessed using the motor examination section of the UPDRS and the SPES/SCOPA motor evaluation
- Patients must be willing and able to give written informed consent prior to performing an study procedures
- Be in the "ON" State (only for patients who fluctuate between "ON" and "OFF" states)
Exclusion Criteria
- Absence of bradykinesia at the time of assessment
- Hoehn and Yahr stage not available from patient's chart or not assessed between 3 and 180 days prior to clinic visit
- Has received and experimental drug within the last thirty (30) days
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Scores on the UPDRS motor evaluation subscale are equivalent. 4 months
- Secondary Outcome Measures
Name Time Method Correlations between the UPDRS motor examination bradykinesis subscale and the remaining UPDRS motor examination items, Hoeh and Yahr stage, Schwab and England scale, and SPES/SCOPA motor evaluation. 4 months